{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:38:35Z","timestamp":1790163515954,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40265-018-1022-3","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T04:56:48Z","timestamp":1543813008000},"page":"1903-1910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Daunorubicin\/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia"],"prefix":"10.1007","volume":"78","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"1022_CR1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): acute myeloid leukemia (version 2.2018). 2018. \n                    http:\/\/www.nccn.org\n                    \n                  . Accessed 19 Nov 2018."},{"issue":"31","key":"1022_CR2","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt Ostgard","year":"2015","unstructured":"Granfeldt Ostgard LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641\u20139.","journal-title":"J Clin Oncol"},{"key":"1022_CR3","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.2147\/OTT.S141212","volume":"11","author":"EC Chen","year":"2018","unstructured":"Chen EC, Fathi AT, Brunner AM. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018;11:3425\u201334.","journal-title":"Onco Targets Ther."},{"issue":"7","key":"1022_CR4","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137\u201345.","journal-title":"Blood"},{"issue":"16","key":"1022_CR5","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1002\/cncr.30704","volume":"123","author":"PC Boddu","year":"2017","unstructured":"Boddu PC, Kantarjian HM, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017;123(16):3050\u201360.","journal-title":"Cancer"},{"issue":"13","key":"1022_CR6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2217\/fon-2017-0607","volume":"14","author":"AW Tolcher","year":"2018","unstructured":"Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex\u00ae development platform. Future Oncol. 2018;14(13):1317\u201332.","journal-title":"Future Oncol."},{"key":"1022_CR7","unstructured":"Jazz Pharmaceuticals. VYXEOS\u2122 (daunorubicin and cytarabine) liposome for injection, for intravenous use: US prescribing information. 2017. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 19 Nov 2018."},{"key":"1022_CR8","unstructured":"European Medicines Agency. Vyxeos 44\u00a0mg\/100\u00a0mg powder for concentrate for solution for infusion: EU summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed 19 Nov 2018."},{"issue":"7","key":"1022_CR9","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","volume":"5","author":"LD Mayer","year":"2006","unstructured":"Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1022_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","volume":"33","author":"P Tardi","year":"2009","unstructured":"Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129\u201339.","journal-title":"Leuk Res"},{"issue":"9","key":"1022_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","volume":"34","author":"WS Lim","year":"2010","unstructured":"Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214\u201323.","journal-title":"Leuk Res"},{"issue":"7","key":"1022_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","volume":"39","author":"HP Kim","year":"2011","unstructured":"Kim HP, Gerhard B, Harasym TO, et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011;39(7):741\u201350.","journal-title":"Exp Hematol"},{"key":"1022_CR13","doi-asserted-by":"publisher","unstructured":"Di Y, Wasan EK, Cawthray J, et al. Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells. Drug Dev Ind Pharm. 2018. \n                    https:\/\/doi.org\/10.1080\/03639045.2018.1513026\n                    \n                  .","DOI":"10.1080\/03639045.2018.1513026"},{"key":"1022_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2016.12.002","volume":"53","author":"MJ Gordon","year":"2017","unstructured":"Gordon MJ, Tardi P, Loriaux MM, et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. 2017;53:39\u201349.","journal-title":"Leuk Res"},{"issue":"8","key":"1022_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","volume":"29","author":"EJ Feldman","year":"2011","unstructured":"Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29(8):979\u201385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1022_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00280-017-3484-5","volume":"81","author":"M Nikanjam","year":"2018","unstructured":"Nikanjam M, Capparelli EV, Lancet JE, et al. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018;81(1):171\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"1022_CR17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","volume":"36","author":"EJ Feldman","year":"2012","unstructured":"Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36(10):1283\u20139.","journal-title":"Leuk Res"},{"issue":"21","key":"1022_CR18","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","volume":"123","author":"JE Lancet","year":"2014","unstructured":"Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239\u201346.","journal-title":"Blood"},{"key":"1022_CR19","doi-asserted-by":"crossref","unstructured":"Lin TL, Newell LF, Stuart RK, et al. CPX-351 ((cytarabine:daunorubicin) liposome injection, (Vyxeos)) does not prolong QTcF intervals, requires no dose adjustment for impaired renal function and induces high rates of complete remission in acute myeloid leukemia [abstract no. 2510]. Blood. 2015;126(23).","DOI":"10.1182\/blood.V126.23.2510.2510"},{"issue":"26","key":"1022_CR20","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684\u201392.","journal-title":"J Clin Oncol"},{"key":"1022_CR21","doi-asserted-by":"crossref","unstructured":"Lancet JE, Ritchie EK, Uy GL, et al. Efficacy and safety of CPX-351 versus 7\u2009+\u20093 in older adults with secondary acute myeloid leukemia: combined subgroup analysis of phase 2 and phase 3 studies [abstract no. 2657]. Blood. 2017;130(Suppl 1).","DOI":"10.1016\/j.clml.2017.07.074"},{"key":"1022_CR22","doi-asserted-by":"crossref","unstructured":"Lin TL, Uy GL, Wieduwilt MJ, et al. Subanalysis of patients with secondary acute myeloid leukemia (sAML) with refractory anemia with excess of blasts in transformation (RAEB-T) enrolled in a phase 3 study of CPX-351 versus conventional 7\u2009+\u20093 cytarabine and daunorubicin [abstract no. 1698]. Blood. 2017;130(Suppl 1).","DOI":"10.1016\/j.bbmt.2017.12.209"},{"key":"1022_CR23","doi-asserted-by":"crossref","unstructured":"Lancet JE, Rizzieri D, Schiller GJ, et al. Overall survival (OS) with CPX-351 versus 7\u2009+\u20093 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): subgroup analysis of a phase III study [abstract no. 7035]. J Clin Oncol. 2017;35(Suppl 15).","DOI":"10.1200\/JCO.2017.35.15_suppl.7035"},{"key":"1022_CR24","doi-asserted-by":"crossref","unstructured":"Medeiros BC, Hogge D, Newell LF, et al. Overall survival and transplantation in patients with FLT3 mutations: subgroup analysis of a phase 3 study of CPX-351 versus 7\u2009+\u20093 in older adults with newly diagnosed, high-risk acute myeloid leukemia [abstract no. P210]. Haematologica. 2017;102(Suppl 2):53\u20134.","DOI":"10.1016\/j.clml.2017.07.071"},{"issue":"Suppl 2","key":"1022_CR25","first-page":"379","volume":"102","author":"JE Kolitz","year":"2017","unstructured":"Kolitz JE, Strickland SA, Cortes JE, et al. Efficacy by outpatient vs inpatient administration of consolidation: subgroup analysis of a phase 3 study of CPX-351 versus 7\u2009+\u20093 in older adults with newly diagnosed, high-risk acute myeloid leukemia [abstract no. E922]. Haematologica. 2017;102(Suppl 2):379.","journal-title":"Haematologica"},{"key":"1022_CR26","doi-asserted-by":"crossref","unstructured":"Kolitz JE, Strickland SA, Cortes JE, et al. Outcomes in older patients with newly diagnosed, high-risk\/secondary acute myeloid leukemia (sAML) who received consolidation in a phase 3 study of CPX-351 versus conventional 7+3\/5+2 cytarabine and daunorubicin. Society of Hematologic Oncology Sixth Annual Meeting. 2018.","DOI":"10.1016\/j.clml.2018.07.064"},{"key":"1022_CR27","unstructured":"Cortes JE, Medeiros BC, Uy GL, et al. Outcomes by number of induction cycles with CPX-351 versus 7\u2009+\u20093 chemotherapy in older adults with newly diagnosed, high-risk\/secondary acute myeloid leukemia (sAML) [abstract no. PF239]. In: 23rd Congress of the European haematology association. 2018."},{"key":"1022_CR28","doi-asserted-by":"crossref","unstructured":"Chung KC, Ryan RJ, Louie AC. CPX-351 for the treatment of newly diagnosed, therapy-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (AML-MRC): an analysis of clinical benefit [abstract no. PCN9]. Value Health. 2018;21(Suppl 1):S15.","DOI":"10.1016\/j.jval.2018.04.087"},{"key":"1022_CR29","unstructured":"Medeiros BC, Lancet JE, Cortes JE, et al. Rates of adverse events per patient-year in a randomized, phase 3 study of CPX-351 versus 7\u2009+\u20093 in older adults with newly diagnosed, treatment-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes [abstract no. 1366]. Blood. 2017;130(Suppl 1)."},{"key":"1022_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.02.014","volume":"391","author":"A Dicko","year":"2010","unstructured":"Dicko A, Kwak S, Frazier AA, et al. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm. 2010;391:248\u201359.","journal-title":"Int J Pharm"},{"key":"1022_CR31","unstructured":"National Institute for Health and Care Excellence. Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia. 2018. \n                    http:\/\/www.nice.org.uk\n                    \n                  . Accessed 19 Nov 2018."},{"issue":"2","key":"1022_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/cncr.28974","volume":"121","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121(2):234\u201342.","journal-title":"Cancer"},{"key":"1022_CR33","unstructured":"US FDA. Vyxeos\u00ae (daunorubicin and cytarabine) liposome: multi-discipline review. 2017. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 19 Nov 2018."},{"key":"1022_CR34","doi-asserted-by":"crossref","unstructured":"Kubal TE, Salamanca C, Komrokji RS, et al. Safety and feasibility of outpatient induction chemotherapy with CPX-351 in selected older adult patients with newly diagnosed AML [abstract no. e19013]. J Clin Oncol. 2018;36(Suppl 15).","DOI":"10.1200\/JCO.2018.36.15_suppl.e19013"},{"issue":"11","key":"1022_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/13696998.2018.1513847","volume":"21","author":"M Hagiwara","year":"2018","unstructured":"Hagiwara M, Sharma A, Chung KC, et al. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J Med Econ. 2018;21(11):1119\u201330.","journal-title":"J Med Econ"},{"issue":"5","key":"1022_CR36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.clinthera.2018.03.012","volume":"40","author":"NC Sacks","year":"2018","unstructured":"Sacks NC, Cyr PL, Louie AC, et al. Burden of acute myeloid leukemia among older, newly diagnosed patients: retrospective analysis of data from the 2010\u20132012 Medicare limited data set. Clin Ther. 2018;40(5):692\u2013703 e2.","journal-title":"Clin Ther"},{"key":"1022_CR37","unstructured":"Jazz Pharmaceuticals. CMS grants new technology add-on payment to Vyxeos\u00ae (daunorubicin and cytarabine) liposome for injection [media release]. 3 Aug 2018. \n                    http:\/\/www.prnewswire.com\n                    \n                  ."},{"key":"1022_CR38","unstructured":"Kansal A, Du M, Herrera-Restrepo O, et al. Cost-effectiveness of CPX-351 versus 7\u2009+\u20093 regimen in the treatment of treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) [abstract no. 4674]. Blood. 2017;130(Suppl 1)."},{"key":"1022_CR39","unstructured":"Jensen IS, Wu E, Sacks N, et al. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective [abstract no. 5615]. Blood. 2017;130(Suppl 1)."}],"updated-by":[{"DOI":"10.1007\/s40265-018-1034-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T00:00:00Z","timestamp":1544572800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-1022-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:25:11Z","timestamp":1575314711000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-1022-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1022-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"3 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}